Retro Biosciences are aiming to improve our lifespan. This is the ultimate goal for the company according to their mission:
Our mission is to increase healthy human lifespan by ten years.
They do not clarify why the aim is exactly ten years, and they also seem to keep their cards close to their chest about how they plan to achieve this. However, they do seem rather confident that their initial capital injection of $180M will be sufficient to keep them going for the rest of this decade, and allow them to reach a proof of concept stage with a solution.
Feel welcome to share your own thoughts on this company in the comment section below. I will be happy to discuss and learn more about how you see their potential in this field.
The solution
While Retro Biosciences remain vague on how they actually envision their solution to take form they have provided some strategic pointers. initially they are aiming at three different paths to investigate.
- Cellular reprogramming
- Plasma-inspired therapeutics
- Autophagy
The overarching theme being to investigate and identify aging mechanisms in each of the above mentioned fields. Importantly, these aging mechanisms need to have already shown a proof of concept in mammals and have a feasible path to translate to humans.
The company
Retro Biosciences operate out of Redwood City, California, USA, and from what we know was founded in 2021 with the founding team being Joe Betts-LaCroix, Matt Buckley, and Sheng Ding. The CEO of the company, Joe Betts-LaCroix, has previously founded a number of companies related to healthcare.
The company received significant media attention due to OpenAI’s CEO Sam Altman investing a reported $180M in the company. Taking into account that Sam Altman has been heading Y Combinator from 2014-2019, one of the largest startup incubators in the world, we can assume that he would know if this startup has their things in order.
Read about more anti-aging companies on this website through this link.
